Do you want to read an article? Please log in or register.
GMMG-CONCEPT: Isatuximab plus KRd leads to high and sustained MRD negativity in transplant-eligible patients with high-risk NDMM
Multiple Myeloma (MM)
EHA 2025
Related content
ASH 2024
Multiple Myeloma (MM)
Isatuximab plus RVd yields deep MRD negativity and PFS benefit in transplant-eligible patients with NDMM
ASH 2024
Multiple Myeloma (MM)
EMN15/HOVON147: Adding carfilzomib to Rd significantly improves MRD negativity rates in patients with high-risk smoldering multiple myeloma
SABCS 2024
Breast Cancer
PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer
Multiple Myeloma (MM)
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
J Clin Oncol
Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, Schroers R, von Metzler I, Hänel M, Mann C, Leypoldt LB, Heilmeier B, Huhn S, Vogel SK, Hundemer M, Scheid C, Blau IW, Luntz S, Weinhold N, Tichy D, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Benner A, Hoffmann M, Weisel KC, Salwender HJ, Goldschmidt H, German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators, German-speaking Myeloma Multicenter Group (GMMG) HD7
doi: 10.1200/JCO-24-02266
ESMO 2024
Gynecologic Cancer
KEYNOTE-A18: Pembrolizumab plus chemoradiotherapy improves PFS and OS in patients with high-risk, locally advanced cervical cancer
SABCS 2024
Breast Cancer
OlympiA: Olaparib continues to demonstrate improved OS, IDFS and DDFS in patients with BRCA1/2-mutated HER2-negative high-risk early breast cancer
Multiple Myeloma (MM)
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database
Blood Cancer J
Rajkumar SV, Mateos MV, Schaeffer M, Lin X, Bathija S, Gupta-Werner N, Lam A, Carson R, Dennis R, Kaila S, Matt K, Duran J, Lonial S
doi: 10.1038/s41408-024-01170-z
EHA 2025
Leukemia
Blinatumomab led to high remission and MRD negativity rates in routine clinical practice for adult Ph-negative B-cell ALL
COMMENTED
Gynecologic Cancer
ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer
★ 0
Recommended and commented by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol
Van Gorp T, Cibula D, Lv W, Backes F, Ortaç F, Hasegawa K, Lindemann K, Savarese A, Laenen A, Kim YM, Bodnar L, Barretina-Ginesta MP, Gilbert L, Pothuri B, Chen X, Flores MB, Levy T, Colombo N, Papadimitriou C, Buchanan T, Hanker LC, Eminowicz G, Rob L, Black D, Lichfield J, Lin G, Orlowski R, Keefe S, Lortholary A, Slomovitz B, ENGOT-en11/GOG-3053/KEYNOTE-B21 investigators
doi: 10.1016/j.annonc.2024.08.2242